Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Prostate cancer
Phase 1 FLT (thymidine analog PET tracer) vs CSE-MRI (water–fat chemical shift) for active marrow mapping
University of Wisconsin–Madison is running this small, paired-imaging study in men with metastatic PSMA-positive castration-resistant prostate cancer who are already scheduled for 177Lu-PSMA radiopharmaceutical…
NCT07609225 Exploratory - New trial
Prostate cancer
Phase 2 zanzalintinib c-MET/VEGFR tyrosine kinase inhibitor in visceral/soft-tissue mCRPC.
This single-arm Phase 2 study tests zanzalintinib, an oral small-molecule multi-kinase inhibitor targeting c-MET (HGFR) and VEGFR pathways that drive tumor growth, invasion, and angiogenesis. The trial enrolls men…
NCT07608718 Exploratory - New trial Spotlight
Breast cancer
Phase 2 BETTER trial tests pembrolizumab PD-1 blockade with taxane/platinum chemo de-escalation.
MD Anderson Cancer Center is running this Phase 2 neoadjuvant study in high-risk, early-stage triple-negative breast cancer (clinical stage T1cN1-2 or T2-4N0-2) to see whether blood-based ctDNA and breast MRI can…
NCT07610525 Exploratory - New trial
Breast cancer
Phase 1/2 REPEAT tests accelerated partial-breast re-irradiation (aPBI) using external-beam radiation.
Dartmouth-Hitchcock Medical Center is running this prospective Phase 1/2 study to see whether re-irradiating only the partial breast (accelerated partial-breast irradiation, aPBI) yields acceptably low acute toxicity…
NCT07612254 Exploratory - New trial
Breast cancer
Phase 2 elacestrant SERD + trastuzumab/pertuzumab HER2 mAbs in triple-positive breast cancer.
This Phase 2 NYU Langone Health investigator-led study (ELATE; NCT07612215) evaluates the safety and anti-tumor activity of adding elacestrant—an oral selective estrogen receptor degrader (SERD) that binds ER and…
NCT07612215 Exploratory - New trial Spotlight
Ovarian cancer
Phase 3 azenosertib WEE1 inhibitor vs chemotherapy in Cyclin E1+ platinum-resistant HGS ovarian cancer.
This global, randomized, open-label Phase 3 study (ASPENOVA; also referenced as GOG-3147/ENGOT-ov109/APGOT-OV27) tests whether azenosertib (ZN-c3)—a first-in-class, oral WEE1 kinase inhibitor from Zentalis…
NCT07546500 Registrational - New trial
Acute lymphoblastic leukemia
Phase 1 LP-118 dual BCL-2/BCL-XL inhibitor with ponatinib + blinatumomab in Ph+ ALL
This Phase 1, Wake Forest University Health Sciences–sponsored study tests whether adding LP-118 (an oral small-molecule inhibitor of the anti‑apoptotic proteins BCL-2 and BCL-XL) can be safely combined with a modern…
NCT07614022 Exploratory - New trial Spotlight
Acute myeloid leukemia and MDS
Phase 2 revumenib menin inhibitor triplet with azacitidine + venetoclax in KMT2A-rearranged AML.
UNC Lineberger’s RAVEN study (NCT07605949) evaluates an all-oral/SC intensive-lower regimen combining revumenib (a menin–KMT2A/MLL interaction inhibitor that downregulates leukemogenic HOX/MEIS programs) with…
NCT07605949 Exploratory - New trial
Pancreatic cancer
Phase 1 64Cu-DOTA-A2DM PET: PSCA-targeted immunoPET tracer (anti-PSCA scFv-Fc2)
This Phase 1 City of Hope study evaluates whether 64Cu-DOTA-A2 scFv-Fc2 DM (64Cu-DOTA-A2DM) can safely and feasibly generate high-quality PET images in locally advanced or metastatic, unresectable PSCA-expressing…
NCT07608627 Exploratory - New trial
Brain and CNS tumors
Phase 2 FG001 uPAR-targeted near-infrared fluorescent imaging agent for high-grade glioma surgery.
This prospective, single-group, open-label Phase 2 study tests whether FluoGuide A/S’s FG001 can improve intraoperative visualization of malignant tissue during first surgery for newly diagnosed high-grade glioma.…
NCT07609472 Exploratory - New trial
Colorectal cancer
Phase 2b HRX215 (darizmetinib) MKK4 inhibitor to accelerate liver regeneration after PVE.
This Phase 2b, randomized, placebo-controlled study at Mayo Clinic tests whether HRX215 (darizmetinib)—an oral small-molecule inhibitor of MKK4 (MAP2K4)—can increase future liver remnant growth after portal vein…
NCT07612007 Exploratory - New trial
Colorectal cancer
Phase 1 Ad5.F35-hGUCY2C-PADRE + Lm-GUCY2C vaccines, GUCY2C-targeted T-cell immunotherapy
This open-label, non-randomized Phase 1 dose-escalation study at Thomas Jefferson University tests a heterologous prime-boost cancer vaccine strategy targeting GUCY2C, an intestinal lineage antigen commonly retained…
NCT07417488 First-in-human - New trial
Multiple solid tumors
Phase 1 IM-1617 undisclosed RTK–targeting ADC with TOP1 inhibitor payload in solid tumors
Immunome, Inc. is running a first-in-human, open-label Phase 1 dose-escalation (Part A) followed by dose-expansion (Part B) study to define the recommended dose/schedule and assess early antitumor activity of IM-1617…
NCT07578571 First-in-human - New trial
Multiple solid tumors
Phase 1 NEOK002 EGFR×MUC1 bispecific ADC with topoisomerase-1 inhibitor payload
NEOK Bio’s first-in-human, open-label Phase 1 study (NCT07612189) evaluates NEOK002, an EGFR- and MUC1-binding bispecific antibody-drug conjugate (ABL209) carrying an exatecan-class topoisomerase I inhibitor payload…
NCT07612189 First-in-human - New trial
Multiple solid tumors
Phase 1 BI 3819026 anti-LAYN antibody + ezabenlimab PD-1 inhibitor in solid tumors.
This first-in-human, open-label, multicenter Phase 1 dose-escalation study tests BI 3819026 (a Boehringer Ingelheim anti-LAYN/layilin antibody; LAYN is a hyaluronan-binding cell-surface protein implicated in tumor…
NCT07607678 First-in-human - New trial
Multiple solid tumors
Phase 1 CS231295 Aurora B–selective multi-kinase inhibitor in advanced solid tumors and glioma
This Phase 1, single-arm, open-label, multicenter dose-escalation study evaluates CS231295 in adults with unresectable, advanced/recurrent/metastatic solid tumors (including a glioma cohort) who have exhausted…
NCT07612488 First-in-human - New trial
Multiple solid tumors
Phase 1 NEOK001 B7-H3×ROR1 bispecific ADC targets dual tumor antigens in solid tumors.
This first-in-human, open-label Phase 1 study evaluates NEOK001 (also referenced as ABL206), a bispecific antibody-drug conjugate from NEOK Bio, Inc. designed to bind two tumor-associated surface targets—B7-H3…
NCT07612176 First-in-human - New trial
Multiple solid tumors
Phase 1/2 UI-102 cholesteryl-pullulan nanoparticle TLR7/8 agonist immunostimulant in solid tumors.
This first-in-human, open-label Phase 1/2 trial evaluates UI-102, a small-molecule Toll-like receptor 7/8 (TLR7/8) agonist formulated in a cholesteryl pullulan (CHP) nanoparticle for IV infusion, sponsored by United…
NCT07605962 First-in-human - Trial result Spotlight
Breast cancer
Dato-DXd (TROP2 ADC) + durvalumab (PD-L1) drives ~80% ORR and 14-mo mPFS in 1L metastatic TNBC (BEGONIA)
Dato-DXd is a TROP2-directed antibody–drug conjugate delivering a topoisomerase I inhibitor payload (deruxtecan), combined here with durvalumab (anti–PD-L1) as first-line therapy in unresectable locally…
NCT03742102 - Trial result
Breast cancer
Trastuzumab+pertuzumab dual HER2 blockade with endocrine therapy matches 5-year survival despite lower pCR in HR+/HER2+ eBC
Trastuzumab (HER2 mAb) plus pertuzumab (HER2 dimerization-blocking mAb) were given for 12 weeks neoadjuvantly with either endocrine therapy (ET) or weekly paclitaxel in the randomized Phase II open-label WSG TP-II…
NCT03272477 - Trial result Spotlight
Non-small cell lung cancer
Zoldonrasib (RMC-9805) RAS(ON) KRAS G12D inhibitor drives 52% ORR and 11.1-mo PFS in pretreated NSCLC
Zoldonrasib (RMC-9805) is an oral, covalent, KRAS G12D-selective “RAS(ON)” tri-complex inhibitor that targets the active (GTP-bound) state; updated monotherapy data come from an ongoing Phase 1/1b dose-escalation…
NCT06040541 - Trial result Spotlight
Non-small cell lung cancer
Elisrasib (D3S-001) GDP-bound KRAS G12C inhibitor posts 56% ORR in 2L+ NSCLC and 32% post–G12Ci
Elisrasib is an oral, next-generation KRAS G12C inhibitor designed to bind the GDP-bound state and sustain target engagement despite growth factor–driven nucleotide exchange (a hypothesized resistance lever for…
NCT05410145 - Trial result
Brain and CNS tumors
Preop DSC-MRI perfusion (CBV/CBF) predicts poorer survival in high-grade glioma despite 96% EOR with iMRI
Preoperative MR perfusion (DSC-MRI CBV/CBF) and intraoperative MRI (iMRI) were evaluated in a prospective, single-center pilot cohort of newly diagnosed high-grade glioma (WHO grade 3 astrocytoma + glioblastoma;…
- Trial result
Melanoma
Tebentafusp (gp100×CD3 ImmTAC) Doubles 5-Year OS to 16% in HLA-A*02:01+ Metastatic Uveal Melanoma
Tebentafusp is a first-in-class TCR–anti-CD3 bispecific fusion protein (ImmTAC) that redirects T cells to gp100 peptide presented by HLA-A*02:01 on uveal melanoma cells. In the international, open-label Phase 3…
NCT03070392 - Trial result
Melanoma
Pegenzileukin (SAR444245) non‑α IL‑2 (IL‑2Rβγ agonist) + PD‑1 cemiplimab hits 40% ORR in metastatic melanoma; 56% ORR in advanced cSCC
Pegenzileukin is a pegylated recombinant IL‑2 variant engineered to avoid IL‑2Rα binding (aiming to reduce classic IL‑2 toxicities/Treg expansion) while engaging IL‑2Rβγ to expand NK and CD8 T cells; here it was…
NCT04913220 - Trial result
Ovarian cancer
IMNN-001 (intraperitoneal IL-12 plasmid gene therapy) + carbo/taxol nudges PFS/OS upward in newly diagnosed advanced ovarian cancer
IMNN-001 is an intraperitoneal immunotherapy nanoparticle delivering a DNA plasmid encoding IL-12, given weekly alongside neoadjuvant/adjuvant carboplatin/paclitaxel around interval debulking surgery in the…
- Trial result
Sarcoma and GIST
Atezolizumab (PD‑L1) in ASPS shows low late toxicity beyond 2 years of exposure
Atezolizumab is an anti–PD‑L1 checkpoint inhibitor; in the Phase 2 NCT03141684 trial in unresectable/metastatic alveolar soft part sarcoma (ASPS), this AACR 2026 update focused on late safety among patients treated…
NCT03141684 - Trial result
Uterine (endometrial) cancer
Lenvatinib (VEGFR/FGFR TKI) + pembrolizumab (PD-1) improves OS/PFS after (neo)adjuvant platinum in endometrial cancer
Lenvatinib is an oral multi-kinase antiangiogenic TKI (VEGFR1–3/FGFR1–4, etc.) combined with pembrolizumab, a PD-1 inhibitor, and was analyzed in two Phase 3 randomized trials restricted to patients whose only prior…
- Trial result
Head and neck cancer
Pembrolizumab (PD-1) + nab-paclitaxel (albumin-bound taxane) + platinum hits 64% ORR and 12.7-mo PFS in 1L R/M HNSCC
Pembrolizumab is an anti–PD-1 antibody combined here with nab-paclitaxel (a solvent-free, albumin-bound paclitaxel) plus cisplatin or carboplatin as first-line therapy in a single-arm Phase 2 trial in treatment-naïve…
NCT04857164 - Trial result
Non-small cell lung cancer
Pembrolizumab (PD-1) ± carboplatin/pemetrexed shows manageable grade≥3 toxicity in ≥70yo lung adenocarcinoma
Pembrolizumab is an anti–PD-1 checkpoint inhibitor; here it was given first-line as monotherapy or with carboplatin+pemetrexed in a national, nonrandomized open-label Phase II trial in adults aged ≥70 years with…
NCT04533451
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.